Understanding the risk factors of hemagglutinase-associated hypofibrinogenemia can improve the prognosis of patients.

We editorialized on this study published by Zou . Gastrointestinal bleeding is a common clinical symptom, and hemocoagulase is frequently used to treat hemorrhagic conditions. However, studies have shown that hemocoagulase treatment may induce acquired hypofibrinogenemia, further aggravating the bleeding. Zou retrospectively analyzed 109 gastrointestinal bleeding cases to explore the hazards underlying hypofibrinogenemia induced by hemocoagulase, and identified higher total dose of hemocoagulase and female sex, as well as low baseline fibrinogen levels as significant hazards. Consequently, clinicians should be aware of both intrinsic and extrinsic risk factors when using hemocoagulase among this patient population, and remain vigilant for the potential development of hemocoagulase-induced hypofibrinogenemia.